243 related articles for article (PubMed ID: 25615768)
1. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization.
Ray CE; Brown AC; Green TJ; Winston H; Curran C; Kreidler SM; Glueck DH; Rochon PJ
AJR Am J Roentgenol; 2015 Feb; 204(2):440-7. PubMed ID: 25615768
[TBL] [Abstract][Full Text] [Related]
2. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
5. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
6. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
10. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
11. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
[TBL] [Abstract][Full Text] [Related]
13. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
14. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
15. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
[TBL] [Abstract][Full Text] [Related]
16. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
17. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
[TBL] [Abstract][Full Text] [Related]
18. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
19. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.
Zhong JH; Ke Y; Gong WF; Xiang BD; Ma L; Ye XP; Peng T; Xie GS; Li LQ
Ann Surg; 2014 Aug; 260(2):329-40. PubMed ID: 24096763
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
Burrel M; Reig M; Forner A; Barrufet M; de Lope CR; Tremosini S; Ayuso C; Llovet JM; Real MI; Bruix J
J Hepatol; 2012 Jun; 56(6):1330-5. PubMed ID: 22314428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]